IRIS
GIORGIO, Carmine
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.792
EU - Europa 3.147
AS - Asia 2.690
SA - Sud America 416
AF - Africa 158
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.207
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.697
SG - Singapore 1.040
IT - Italia 940
CN - Cina 914
FI - Finlandia 443
IE - Irlanda 426
DE - Germania 393
BR - Brasile 344
SE - Svezia 342
HK - Hong Kong 198
VN - Vietnam 167
IN - India 125
GB - Regno Unito 96
NL - Olanda 91
TR - Turchia 89
ZA - Sudafrica 87
FR - Francia 86
UA - Ucraina 77
RU - Federazione Russa 71
BE - Belgio 50
CA - Canada 48
CI - Costa d'Avorio 43
AR - Argentina 33
MX - Messico 29
AT - Austria 26
BD - Bangladesh 24
ID - Indonesia 23
JP - Giappone 22
KR - Corea 22
CZ - Repubblica Ceca 20
PL - Polonia 17
ES - Italia 16
PK - Pakistan 14
EC - Ecuador 12
LT - Lituania 11
RO - Romania 11
IQ - Iraq 10
EG - Egitto 7
VE - Venezuela 7
CH - Svizzera 6
CO - Colombia 6
AL - Albania 5
CL - Cile 5
HU - Ungheria 5
MA - Marocco 5
PY - Paraguay 5
UZ - Uzbekistan 5
JM - Giamaica 4
JO - Giordania 4
KG - Kirghizistan 4
PA - Panama 4
TN - Tunisia 4
DK - Danimarca 3
EU - Europa 3
HN - Honduras 3
KE - Kenya 3
MY - Malesia 3
NP - Nepal 3
PE - Perù 3
RS - Serbia 3
SA - Arabia Saudita 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
CR - Costa Rica 2
DZ - Algeria 2
IL - Israele 2
IR - Iran 2
OM - Oman 2
SC - Seychelles 2
SN - Senegal 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CM - Camerun 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MC - Monaco 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TM - Turkmenistan 1
VG - Isole Vergini Britanniche 1
Totale 11.207
Salva come PNG Salva come JPEG
Città #
Dallas 1.619
Singapore 532
Dublin 426
Ashburn 398
Chandler 393
Parma 340
Ann Arbor 282
Santa Clara 261
Beijing 217
Hong Kong 195
Munich 174
Boardman 160
Dearborn 143
Helsinki 94
Shanghai 94
Jacksonville 87
Johannesburg 84
New York 83
Nanjing 76
Hefei 75
Los Angeles 74
Izmir 70
Ho Chi Minh City 62
Princeton 60
Bremen 59
Wilmington 55
Abidjan 43
Bologna 43
Hanoi 43
Brussels 40
Columbus 37
São Paulo 37
Chicago 34
Shenyang 31
San Mateo 30
Bangalore 27
Milan 27
Moscow 27
Guangzhou 26
Kunming 26
London 26
Council Bluffs 25
Turku 25
Brescia 21
Buffalo 21
Modena 21
Toronto 20
Jakarta 19
Jinan 19
Lubbock 19
Seoul 19
Tokyo 19
Nanchang 18
Nuremberg 18
Seattle 18
Vienna 18
Düsseldorf 17
Frankfurt am Main 17
Fremont 17
Hebei 17
Des Moines 16
The Dalles 16
Changsha 15
Grafing 15
Reggio Emilia 15
Houston 14
Jiaxing 14
Woodbridge 14
Orem 13
Rio de Janeiro 13
Tianjin 13
Belo Horizonte 12
Brooklyn 12
Dalmine 12
Hangzhou 12
Montreal 12
Boston 11
Brno 11
Münster 11
Piacenza 11
Amsterdam 10
Ankara 10
Bengaluru 10
Mexico City 10
Phoenix 10
Chennai 9
Concesio 9
Curitiba 9
Denver 9
Haiphong 9
San Francisco 9
Stockholm 9
Warsaw 9
Brasília 8
Hyderabad 8
Leuven 8
Ottawa 8
Poplar 8
Rome 8
Zhengzhou 8
Totale 7.418
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.634
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 263
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 228
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 209
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 208
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 196
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 188
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 184
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 181
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 178
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation 173
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 170
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 166
Multi-Target CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach 163
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 161
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 157
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 156
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 154
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 152
Hypericin - apomyoglobin an enhanced photosensitizer complex for the treatment of tumor cells 152
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 151
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 150
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 147
Enhanced photosensitizing properties of protein bound curcumin 147
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 146
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 143
Perturbation of The EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites 142
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 141
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 139
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 137
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 135
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 134
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 133
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 132
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 131
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 130
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 130
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 128
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 127
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 127
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 126
Discovery of small-molecule targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases 124
Structure activity relationship of new EphA2 ligands 123
Discovery of natural extracts interfering with EphA2-ephrinA1 system 122
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 122
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 121
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 121
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 120
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 119
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 118
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 118
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 116
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 116
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 114
Benzofuran-2-Carboxamide Derivatives as Immunomodulatory Agents Blocking the CCL20-Induced Chemotaxis and Colon Cancer Growth 108
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 108
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 108
Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept 102
Investigation on the anti-inflammatory properties of Ocotea quixos Lam. essential oil. 101
Ocotea quixos Lam. essential oil: In vitro and in vivo investigation on its anti-inflammatory properties. 101
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present) 99
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 99
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 99
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 98
Target-hopping: a useful approach to identify novel Eph receptor antagonists 96
Therapeutic perspectives of Eph–ephrin system modulation 92
Ephrin or not? Six tough questions on Eph targeting 88
Drug discovery: In silico dry data can bypass biological wet data? 86
Su1816–Protection by Ccr6 Blockade in a Murine Model of Crohn’s Disease 85
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 78
UNIPR1331: SMALL EPH/EPHRIN ANTAGONIST BENEFICIAL IN INTESTINAL INFLAMMATION BY INTERFERING WITH TYPE-B SIGNALLING 74
Targeting Eph/ephrin system in cancer therapy 74
Effects of CCL20/CCR6 modulators in a T cell adoptive transfer model of colitis 69
Studies on the antiplatelet and antithrombotic profile of anti-inflammatory coumarin derivatives 64
Protection by Eph/ephrin antagonists against TNBS-induced colitis: effects of the route of administration 54
Totale 11.386
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.813
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.813
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021325 0 0 0 0 0 48 65 36 79 36 33 28
2021/2022539 24 23 27 108 36 27 45 44 36 40 18 111
2022/20231.650 161 172 77 133 185 175 42 89 505 27 56 28
2023/2024693 44 41 36 35 47 129 67 53 27 47 75 92
2024/20252.333 98 115 132 117 251 243 176 149 296 200 204 352
2025/20263.936 436 714 1.592 426 642 126 0 0 0 0 0 0
Totale 11.386